ArriVent BioPharma, Inc.
AVBP
$34.00
$0.180.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.19M | 24.18M | 21.08M | 19.07M | 17.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 156.87M | 177.53M | 162.42M | 148.33M | 140.41M |
| Operating Income | -156.87M | -177.53M | -162.42M | -148.33M | -140.41M |
| Income Before Tax | -145.44M | -166.50M | -151.17M | -136.98M | -127.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -145.44 | -166.50 | -151.17 | -136.98 | -127.46 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -145.44M | -166.50M | -151.17M | -136.98M | -127.46M |
| EBIT | -156.87M | -177.53M | -162.42M | -148.33M | -140.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.52 | -4.46 | -4.24 | -4.02 | -3.78 |
| Normalized Basic EPS | -2.20 | -2.79 | -2.65 | -2.51 | -2.36 |
| EPS Diluted | -3.52 | -4.46 | -4.24 | -4.02 | -3.78 |
| Normalized Diluted EPS | -2.20 | -2.79 | -2.65 | -2.51 | -2.36 |
| Average Basic Shares Outstanding | 164.93M | 153.76M | 144.53M | 136.20M | 134.70M |
| Average Diluted Shares Outstanding | 164.93M | 153.76M | 144.53M | 136.20M | 134.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |